Bellevue Group AG Sells 4,484 Shares of Tempus AI, Inc. (NASDAQ:TEM)

Bellevue Group AG lessened its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 89.7% in the third quarter, HoldingsChannel.com reports. The firm owned 516 shares of the company’s stock after selling 4,484 shares during the period. Bellevue Group AG’s holdings in Tempus AI were worth $29,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Captrust Financial Advisors bought a new stake in Tempus AI during the 3rd quarter worth approximately $2,726,000. The Manufacturers Life Insurance Company boosted its position in shares of Tempus AI by 10.2% during the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after buying an additional 2,765 shares during the last quarter. First Horizon Advisors Inc. bought a new stake in Tempus AI during the third quarter worth $30,000. Sumitomo Mitsui Trust Group Inc. raised its position in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Tempus AI during the 3rd quarter valued at $306,000.

Tempus AI Stock Down 0.6 %

TEM opened at $62.59 on Monday. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business has a 50 day simple moving average of $53.15.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Loop Capital lifted their target price on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Bank of America lowered Tempus AI from a “buy” rating to a “neutral” rating and upped their target price for the company from $45.00 to $60.00 in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.22.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.